Nasdaq
$72.63▲ 0.06%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $11.32BShares out 1.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
28- 9.30After-hours26.10.01 05:134Ownership#●●●#●●●
BIO-TECHNE Corp
Insider John L. Higgins of Bio-Techne Corp reported a change in beneficial ownership of securities as of September 28, 2026. This filing serves as a Form 4 statement regarding the insider's equity holdings.…more
$72.63+0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.24After-hours26.09.25 05:524Ownership
BIO-TECHNE Corp
Bio-Techne Corp insider Robert V. Baumgartner filed a Form 4 report regarding changes in beneficial ownership of securities as of September 22, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$72.63+0.06%vs prev closeView filingShare - 9.23After-hours26.09.24 06:088-KKey event
BIO-TECHNE Corp
Bio-Techne shareholders approved the definitive merger agreement with Merck KGaA at a special meeting held on September 23, 2026. The company will become a wholly-owned subsidiary of Merck upon completion of the transaction, which is expected by late 2026 or early 2027, subject to customary closing conditions and regulatory approvals.…more
$72.63+0.06%vs prev closeView filingShare
27 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.8Pre-market26.10.08 21:09#●●●#●●●
Bio-Techne Opens New Bristol Facility for Cell Therapy
Bio-Techne has opened a new GMP manufacturing facility in Bristol to support cell therapy applications. This expansion strengthens the company's global infrastructure and enhances its capacity to assist customers from discovery to commercial production.…more
$72.63+0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.23Pre-market26.09.23 22:22
●●●●●●●● ●●●●● ●●●●●●
Bio-Techne shareholders have officially voted to approve the acquisition agreement proposed by Merck KGaA. The merger will proceed following the successful adoption of the definitive agreement at the special meeting.…more
$72.63+0.06%vs prev closeShareBenzinga - 9.1Pre-market26.09.01 19:36
●●●●●●●● ●●●●● ●●●●●●
Bio-Techne has received official validation from the Science Based Targets initiative (SBTi) for its commitment to reduce Scope 1 and 2 greenhouse gas emissions by 70% by fiscal year 2031. The company also reported significant progress in operational emissions cuts and increased reliance on renewable energy sources during fiscal year 2026.…more
$72.63+0.06%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report